Mark Alley Appointed as President of Cipher Surgical Inc.

As US President of Cipher Surgical Inc. Mark will be responsible for all aspects of US Operations.

A proven global executive leader with extensive experience building and developing teams that consistently exceed revenue goals, Mark has a passion for assessing sales performance and leading teams thru rapid growth.

Mark Alley
Mark Alley, President of Cipher Surgical Inc.

Mark Alley most recently served as Vice President of Sales at Medtronic. He started his professional career at Black and Decker and subsequently also held various leadership roles at Boston Scientific, Johnson and Johnson, Spirox, Entellus Medical, Stryker, Levita Magnetics and Intersect ENT.

“We are delighted to have attracted such a high calibre executive in Mark to manage our US operations” said Andrew Newell, Cipher Surgical’s CEO “At this point in the OpClear’s development towards adoption as a new gold standard in laparoscopic lens clearing, we are experiencing significant interest in the OpClear from the US surgical community. Mark’s management and commercial expertise and experience in surgical devices will be essential to drive sales of the OpClear through our direct sales team and 3rd parties, to fully utilise our operational partnership with MSI out of Chantilly and to develop strategic alliances.”

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.